Table 3 Summary of results of clinical analysis of human samples
MAP | Anti-MAP IgG | |
|---|---|---|
T1DM | 3/10 (30%) | 5/10 (50%) |
T2DM | 1/2 (50%) | 1/2 (50%) |
CONTROL | 3/6 (50%) | 2/6 (33.33%) |
MAP | Anti-MAP IgG | |
|---|---|---|
T1DM | 3/10 (30%) | 5/10 (50%) |
T2DM | 1/2 (50%) | 1/2 (50%) |
CONTROL | 3/6 (50%) | 2/6 (33.33%) |
Gut Pathogens